Overview

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

Status:
NOT_YET_RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.

Phase:

PHASE2

Details

Lead Sponsor:

Fred Hutchinson Cancer Center

Collaborator:

Rising Tide Foundation

Treatments:

Rifaximin
Specimen Handling